Abstracts tagged "matrix metalloproteinase (MMP)"

Abstract Number: 18 • 2012 ACR/ARHP Annual Meeting
Identification of 14-3-3å As a New Subchondral Bone Mediator Involved in Cartilage Degradation During Osteoarthritis
Sabrina Priam Jr.¹, Carole Bougault¹, Xavier Houard², Marjolaine Gosset³, Colette Salvat⁴, Francis Berenbaum⁵ and Claire Jacques¹, ¹Ur-4, Pierre et Marie Curie University Paris VI, Paris, France, ²Sorbonne Universités, UPMC Univ Paris 06, UMRS 938 and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), Paris, France, ³EA 2496, Paris Descartes University, Montrouge, France, ⁴UR4, University Pierre and Marie Curie, Paris, France, ⁵Rheumatology, AP-HP, St Antoine Hospital, Paris, France
Background/Purpose: OA is a complex disease not limited to cartilage degeneration. Indeed, several experiments suggest that subchondral bone remodeling could initiate and/or contribute to cartilage…
Abstract Number: 2520 • 2012 ACR/ARHP Annual Meeting
Suppressor of Cytokine Signaling 3 Is Reduced in Obese Patients with Osteoarthritis and Regulates Leptin Responses in Chondrocytes
Anna Koskinen¹, Katriina Vuolteenaho¹, Riku Korhonen¹, Teemu Moilanen² and Eeva Moilanen¹, ¹The Immunopharmacology Research Group, University of Tampere School of Medicine and Tampere University Hospital, Tampere, Finland, ²Coxa Hospital for Joint Replacement, Tampere, Finland
Background/Purpose: Leptin is an adipokine whose concentrations in circulation are proportional to body fat stores and body mass index (BMI). Initially leptin was discovered to…
Abstract Number: 1804 • 2012 ACR/ARHP Annual Meeting
TNF-Like Protein 1A/Death Receptor 3 Pathway Regulates Osteoclastogenesis and Is Associated with Erosive Disease in Rheumatoid Arthritis
Fraser L. Collins¹, Michael D. Stone², Rhian Goodfellow³, Ernest Choy⁴, Edward C. Wang⁵ and Anwen S. Williams⁶, ¹Section of Rheumatology, Cardiff University, Institute of Infection and Immunity, Cardiff, United Kingdom, ²University Hospital Llandough, Cardiff & Vale University Health Board, Cardiff, United Kingdom, ³Section of Rheumatology, Cardiff University, Cardiff, ENGLAND, United Kingdom, ⁴Section of Rheumatology, Cardiff University School of Medicine, Cardiff, United Kingdom, ⁵Cardiff University, Institute of Infection and Immunity, Cardiff, United Kingdom, ⁶Institute of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom
Background/Purpose: Bone erosion is a characteristic feature of inflammatory arthritides, such as rheumatoid arthritis (RA). Death Receptor 3 (DR3) and its only known ligand TNF-like…
Abstract Number: 1794 • 2012 ACR/ARHP Annual Meeting
Matrix Metalloproteinase 3 and Acute Phase Proteins As Markers of Disease Activity and Radiographic Damage in Early Rheumatoid Arthritis
Mahmood MTM Ally¹, Bridget Hodkinson², Pieter W.A Meyer¹, Eustasius Musenge³, Mohammed Tikly⁴ and Ronald Anderson¹, ¹University of Pretoria, Pretoria, South Africa, ²Rheumatology, University of the Witwatersrand, Johannesburg, South Africa, ³University of Witwatersrand, Johannesburg, South Africa, ⁴Rheumatology, Division of Rheumatology, University of the Witwatersrand, Johannesburg, South Africa
Background/Purpose: Although matrix metalloproteinase-3 (MMP-3) is believed to be intimately involved in the immunopathogenesis of rheumatoid arthritis (RA), relatively little is known about its relationships…
Abstract Number: 1296 • 2012 ACR/ARHP Annual Meeting
An Interim Analysis of the Efficacy of Abatacept in Japanese Biologics-naïve Rheumatoid Arthritis Patients (results from ABROAD study): Comparison of CRP and MMP-3 Level After Treatment with Abatacept Versus Anti-TNF Agents
Masahiro Sekiguchi¹, Kiyoshi Matsui¹, Masayasu Kitano¹, Mitsuo Namiki¹, Koichiro Ohmura², Takao Fujii³, Hideko Nakahara⁴, Keiji Maeda⁴, Hideo Hashimoto⁵, Takanori Kuroiwa⁶, Kenji Miki⁷, Masanori Funauchi⁸, Kazuhiro Hatta⁹, Kenshi Higami¹⁰, Shunzo Namiuchi¹¹, Ichiro Yoshii¹², Teruyuki Nakatani¹³, Takashi Ikawa¹⁴, Takaji Matsutani¹⁵, Kosaku Murakami¹⁶, Satoshi Morita¹⁷, Yutaka Kawahito¹⁸, Norihiro Nishimoto¹⁵, Tsuneyo Mimori¹⁹ and Hajime Sano¹, ¹Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan, ²Department of Rheumatology & Clin Immunology, Kyoto University, Kyoto, Japan, ³Dept of Rheum/Clinical Immun, Graduate School of Medicine,, Kyoto University, Kyoto, Japan, ⁴Division of Allergy, Rheumatology and Connective Tissue Diseases, Department of Internal Medicine, NTT West Osaka Hospital, Osaka, Japan, ⁵Dept of Orthopedic Surgery, Rinku Hashimoto Rheumatology Orthopaedics, Osaka, Japan, ⁶Department of Rheumatology, Yukioka Hospital, Osaka, Japan, ⁷Department of Orthopaedic Surgery, Amagasaki Central Hospital, Amagasaki, Japan, ⁸Division of Hematology and Rheumatology, Department of Medicine, Kinki University Faculty of Medicine, Osaka, Japan, ⁹Department of Internal Medicine, Tenri Yorozu Sodansyo Hospital, Nara, ¹⁰Department of Rheumatology, Higami Hospital, Nara, Japan, ¹¹Department of Rheumatology, Saiseikai Nakatsu Hospital, Osaka, Japan, ¹²Department of Orthopaedic Surgery, Yoshii Hospital, Shimanto, Japan, ¹³Department of Orthopaedic Surgery, Kishiwada City Hospital, Osaka, Japan, ¹⁴Osaka Rehabilitation Hospital, Hannan, Japan, ¹⁵Laboratory of Immune Regulation, Wakayama Medical University, Ibaraki, Japan, ¹⁶Rheumatology and Clinical Immunology, Osaka Red Cross Hospital, Osaka, Japan, ¹⁷Graduate School of Medicine & Medical Center, Department of Biostatistics and Epidemiology, Yokohama City University, Kanagawa, Japan, ¹⁸Department of Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan, ¹⁹Dept of Rheum & Clinical Immun, Kyoto University, Kyoto, Japan
Background/Purpose: Abatacept (ABA) is a recombinant fusion protein consisting of the extracellular domain of human CTLA-4, binding to CD80/86 on antigen presenting cells (APCs) and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].